MedPath

MITSUBISHI TANABE PHARMA CORPORATION

πŸ‡―πŸ‡΅Japan
Ownership
-
Employees
-
Market Cap
-
Website

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: MP-214
First Posted Date
2012-06-25
Last Posted Date
2021-04-13
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
42
Registration Number
NCT01626885

A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: Risperidone
Drug: MP-214
First Posted Date
2012-06-22
Last Posted Date
2021-04-13
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
125
Registration Number
NCT01625897

Safety and Efficacy of MP-214 in Patients With Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: MP-214 9mg
Drug: Risperidone 4mg
Drug: Placebo
Drug: MP-214 3mg
Drug: MP-214 6mg
First Posted Date
2012-06-21
Last Posted Date
2021-04-12
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
512
Registration Number
NCT01625000

Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease

Phase 3
Completed
Conditions
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Interventions
Drug: TA-650
Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
First Posted Date
2012-05-11
Last Posted Date
2018-10-25
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
31
Registration Number
NCT01596335
Locations
πŸ‡―πŸ‡΅

Investigational site, Tokai, Japan

Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

Phase 3
Completed
Conditions
Pediatric Ulcerative Colitis
Interventions
Drug: TA-650
First Posted Date
2012-04-25
Last Posted Date
2019-11-05
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
21
Registration Number
NCT01585155
Locations
πŸ‡―πŸ‡΅

Investigational site, Tohoku, Japan

Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease

Phase 3
Completed
Conditions
Pediatric Crohn's Disease
Interventions
Drug: TA-650
First Posted Date
2012-04-19
Last Posted Date
2019-07-24
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
14
Registration Number
NCT01580670
Locations
πŸ‡―πŸ‡΅

Investigational site, Tohoku, Japan

Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

Phase 3
Completed
Conditions
Behcet Syndrome
Neuro-Behcet's Disease
Behcet's Disease
Interventions
Drug: TA-650
First Posted Date
2012-02-14
Last Posted Date
2016-12-16
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
18
Registration Number
NCT01532570
Locations
πŸ‡―πŸ‡΅

Investigational site, Tohoku, Japan

A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: TA-7284 Low
Drug: TA-7284 High
First Posted Date
2012-01-19
Last Posted Date
2014-06-11
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
24
Registration Number
NCT01512849
Locations
πŸ‡―πŸ‡΅

Reserch site, Kanto, Japan

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Phase 3
Completed
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: Placebo
Drug: MCI-186
Drug: MCI-186 in open label phase
First Posted Date
2011-12-15
Last Posted Date
2018-12-31
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
137
Registration Number
NCT01492686

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Phase 3
Completed
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2011-11-09
Last Posted Date
2014-11-02
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
10
Registration Number
NCT01468584
Locations
πŸ‡―πŸ‡΅

Toranomon Hospital, Minato-ku, Tokyo, Japan

Β© Copyright 2025. All Rights Reserved by MedPath